PTC Therapeutics, Inc. - stock earnings
PTCT Upcoming estimated earnings
| Date | Actual / Estimated EPS | Low Revenue | Actual / Estimated Revenue | High Revenue |
|---|---|---|---|---|
| June 5, 2024 BeforeMarket | - / - | 143.5 million | - / 169.7 million | 209.6 million |
| Aug. 1, 2024 BeforeMarket | - / - | 112.1 million | - / 159.0 million | 186.1 million |
PTCT Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2024Q1 | -91.6 million USD | 210.1 million USD |
| 2023Q4 | -155.8 million USD | 307.1 million USD |
| 2023Q3 | -133.0 million USD | 196.6 million USD |
| 2023Q2 | -198.9 million USD | 213.8 million USD |
| 2023Q1 | -139.0 million USD | 220.4 million USD |
| 2022Q4 | -170.9 million USD | 167.4 million USD |
| 2022Q3 | -109.3 million USD | 217.1 million USD |
| 2022Q2 | -152.1 million USD | 165.5 million USD |
| 2022Q1 | -126.7 million USD | 148.7 million USD |
| 2021Q4 | -143.3 million USD | 165.2 million USD |
| 2021Q3 | -133.6 million USD | 138.7 million USD |
| 2021Q2 | -118.4 million USD | 116.7 million USD |
| 2021Q1 | -128.6 million USD | 117.9 million USD |
| 2020Q4 | -74.4 million USD | 118.9 million USD |
| 2020Q3 | -69.7 million USD | 118.4 million USD |
| 2020Q2 | -181.4 million USD | 75.2 million USD |
| 2020Q1 | -112.7 million USD | 68.3 million USD |
| 2019Q4 | -77.7 million USD | 96.5 million USD |
| 2019Q3 | -60.0 million USD | 71.4 million USD |
| 2019Q2 | -41.8 million USD | 85.5 million USD |
| 2019Q1 | -72.1 million USD | 53.6 million USD |
| 2018Q4 | -48.3 million USD | 86.3 million USD |
| 2018Q3 | -51.0 million USD | 53.6 million USD |
| 2018Q2 | -9.5 million USD | 68.7 million USD |
| 2018Q1 | -19.3 million USD | 56.1 million USD |
| 2017Q4 | 1.3 million USD | 78.0 million USD |
| 2017Q3 | -33.7 million USD | 41.9 million USD |
| 2017Q2 | -17.5 million USD | 48.0 million USD |
| 2017Q1 | -29.1 million USD | 26.5 million USD |
| 2016Q4 | -26.8 million USD | 25.2 million USD |
| 2016Q3 | -35.2 million USD | 23.0 million USD |
| 2016Q2 | -38.9 million USD | 15.6 million USD |
| 2016Q1 | -41.2 million USD | 18.9 million USD |
| 2015Q4 | -50.9 million USD | 12.7 million USD |
| 2015Q3 | -43.2 million USD | 9.8 million USD |
| 2015Q2 | -38.4 million USD | 6.4 million USD |
| 2015Q1 | -37.9 million USD | 5.4 million USD |
| 2014Q4 | -27.3 million USD | 11.6 million USD |
| 2014Q3 | -27.3 million USD | 797000 USD |
| 2014Q2 | -25.1 million USD | 1.4 million USD |
| 2014Q1 | -14.1 million USD | 9.1 million USD |
| 2013Q4 | -17.9 million USD | 3.9 million USD |
| 2013Q3 | -4.4 million USD | 15.5 million USD |
| 2013Q2 | -14.6 million USD | 5.9 million USD |
| 2013Q1 | -14.7 million USD | 6.1 million USD |
| 2012Q4 | -6.3 million USD | 5.9 million USD |
| 2012Q3 | -7.3 million USD | 6.0 million USD |
| 2012Q2 | -6.1 million USD | 6.1 million USD |
| 2012Q1 | -6.6 million USD | 10.8 million USD |
| 2011Q4 | 30.9 million USD | 35.2 million USD |
| 2005Q4 | ? USD | 5.0 million USD |
| 2004Q4 | ? USD | 1.6 million USD |
PTCT Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -626.6 million USD | 937.8 million USD |
| 2022 | -559.0 million USD | 698.8 million USD |
| 2021 | -523.9 million USD | 538.6 million USD |
| 2020 | -438.2 million USD | 380.8 million USD |
| 2019 | -251.6 million USD | 307.0 million USD |
| 2018 | -128.1 million USD | 264.7 million USD |
| 2017 | -79.0 million USD | 194.4 million USD |
| 2016 | -142.1 million USD | 82.7 million USD |
| 2015 | -170.4 million USD | 36.8 million USD |
| 2014 | -93.8 million USD | 23.0 million USD |
| 2013 | -51.6 million USD | 31.3 million USD |
| 2012 | -26.2 million USD | 28.8 million USD |
| 2011 | 30.9 million USD | 99.0 million USD |
| 2005 | ? USD | 5.0 million USD |
| 2004 | ? USD | 1.6 million USD |
PTCT
Price: $31.79
52 week price:
Earnings Per Share: -8.37 USD
P/E Ratio: -2.79
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 588300
Ebitda: -20.6 millionMarket Capitalization: 2.6 billion